Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Low efficacy prompts treatment cessation in statin-intolerant patients taking pravastatin, fluvastatin

10 Dec 2019
Statin side effects are found to be largely related to patients’ negative expectations.

Despite a relatively low rate of relapse of intolerance among patients taking pravastatin or fluvastatin, many of them have eventually discontinued or switched to other medication, reveals a study. Relapse is independently predicted by chronic kidney disease and history of creatine kinase elevation.

The rate of relapse of intolerance during a median follow-up of 37 months was 10.4 percent among pravastatin users and 18.2 percent among fluvastatin users (p=0.04), but the log-rank test showed no between-group difference in the relapse-free rates (p=0.34).

Cessation rates were 36.5 percent for pravastatin and 42.2 percent for fluvastatin (p=0.30). Reasons for discontinuation were varied, which included low efficacy of the agents.

After adjustment, the following factors were found to be independently associated with relapse: chronic kidney disease (hazard ratio [HR], 1.83; p=0.03) and previous creatine kinase elevation (HR, 3.13; p=0.001). Older age (HR, 1.03; p=0.057) and female sex (HR, 1.70; p=0.059) were associated, albeit nonsignificantly, with relapse.

In this retrospective, propensity score-matched cohort study, the authors screened data sourced from a tertiary university hospital between 2006 and 2015. A total of 8.073 patients were screened, of whom 488 with statin intolerance who received pravastatin or fluvastatin with regular follow-up were enrolled. Of these patients, 384 were included in the analysis after propensity-score matching.

The primary outcome variables were relapse of statin intolerance and cessation (ie, discontinuation or switching to other statins) rate for the two agents.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.